“True agility starts with designing the right clinical trial from the beginning”

• In her SCOPE Summit 2026 interview, MEDSIR Business Developement Director Laura Calabuig highlights company’s integrated approach to aligning scientific ambition with operational feasibility.

  
  

• “Biotech and pharma companies are under increasing preasure on shortening timelines, optimizing resources and de-risking deveolpment earlier. Those are the points where MEDSIR adds value”.

Orlando (Florida, US), February 2nd, 2026 - As MEDSIR prepares to make its debut at SCOPE Summit 2026, the leading global forum for innovation in clinical operations, the company is highlighting its commitment to accelerating and optimizing clinical development for biotech and pharma innovators. With the industry facing increasing pressure to deliver faster, smarter, and more efficient clinical trials, MEDSIR enters SCOPE with a clear message: ‘Upgrading your pipeline. Faster.’ In this internal interview, Laura Calabuig, Business Development Director, shares MEDSIR’s perspective on why this moment matters, how the company’s unique model addresses real‑world development challenges, how true agility starts with designing the right clinical trial from the beginning and what attendees can expect when connecting with MEDSIR at this year’s summit.

Laura, this is MEDSIR’s first time attending SCOPE. Why is now the right moment to be here? 

Laura Calabuig, Business Development Director at MEDSIR

SCOPE has become the reference forum where the industry openly discusses how to make clinical development faster, more predictable, and more sustainable. This year feels like the right moment for MEDSIR to be here because the conversation has clearly shifted from whether innovation is needed to how to implement it in real clinical operations. 

Biotech and pharma companies are under increasing pressure to shorten timelines, optimize resources, and de-risk development earlier, especially in complex or investigator-driven studies. That is precisely where MEDSIR adds value. 

Our presence at SCOPE reinforces a clear message: MEDSIR helps sponsors accelerate clinical pipelines by combining scientific leadership, operational flexibility, and a deep understanding of investigator-led research. We don’t just execute trials, we help shape smarter clinical strategies that make development more efficient without compromising scientific rigor. 

MEDSIR’s message for SCOPE is “Upgrading your pipeline. Faster.” What does that mean in practice for potential clients? 

 It means we don’t just execute clinical trials, we make them smarter and more efficient from design to delivery. For biotech, time and capital are critical. For pharma, predictability and operational efficiency matter most. MEDSIR bridges both by : 

·      simplifying protocols,  

·      reducing operational friction

·      accelerating patient enrollment. 

·      A flexible partnership structure tailored to each sponsor’s reality. 

·      Direct access to top investigators worldwide, so trials start faster and recruit better. 

“Upgrading your pipeline. Faster.” reflects our promise: we take existing clinical plans and move them forward with greater speed, clarity, and strategic focus without compromising scientific quality 

What makes MEDSIR’s approach truly different? 

 In clinical trials, when you talk about Agility you talk about designing the right trial from the start. That’s where MEDSIR stands out. 

• We work from early concept strategy to clinical execution, ensuring alignment between scientific objectives and operational feasibility. 

• Our global collaborative research network allows us to bring scientific leaders and operational teams together at a very early stage, which minimizes downstream delays. 

• We are vendoragnostic and build fully customized operational ecosystems for each trial, selecting the best-fit partners rather than forcing sponsors into preestablished structures. 

This integrated, flexible model means fewer protocol amendments, fewer operational bottlenecks, and significantly shorter timelines to first patient in and to full recruitment. 

How does MEDSIR add value specifically for biotech companies preparing their first clinical trials?  

True agility in clinical development starts with designing the right trial from the beginning. That’s where MEDSIR stands out. 

We work end-to-end, from early clinical strategy to execution,ensuring scientific ambition is aligned with real operational feasibility. By bringing investigators, scientific leaders, and operations together at a very early stage, we prevent issues that typically appear later and slow trials down. 

We are fully vendor-agnostic and build customized operational ecosystems for each study, selecting the best-fit partners rather than forcing sponsors into fixed structures. 

The result is fewer protocol amendments, fewer operational bottlenecks, and faster timelines to first patient in and full recruitment. 

And for pharma companies, what is the key benefit of partnering with MEDSIR?  

For pharma, the key value is agility without losing scientific control. They partner with MEDSIR when they need to explore strategic clinical questions quickly, outside the constraints of large internal processes. 

We enable focused, high-impact studies through nimble teams, specialized operational oversight, and fast access to high-performing global investigators. Our collaborative and vendor-agnostic model also provides an unbiased scientific perspective, ensuring decisions are driven by data and scientific merit. 

The result is faster, more efficient execution of strategically relevant trials that complement pharma’s internal capabilities. 

What can attendees expect when meeting MEDSIR at SCOPE?  

They can expect open, practical conversations with a team that understands the real challenges of clinical development. We invite attendees to bring their pipeline questions, and we’ll focus on identifying concrete ways to accelerate timelines, improve trial feasibility, and reduce operational uncertainty. 

Our goal at SCOPE is simple: to demonstrate that MEDSIR is a strategic partner, one that helps sponsors make better clinical decisions faster, not just an operational vendor.